Testing a new PET scan agent for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new PET/CT imaging agent (INR 202) to see if it can better detect advanced solid tumors. It may help doctors see where your cancer is and how active it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have an advanced solid tumor (cancer that has spread or is not curable with surgery)
- You are able to take care of yourself (ECOG score 0 or 1)
- Your major organs (liver, kidneys, bone marrow) are working well
- Your doctor expects you to live at least 6 more months
- You agree to use birth control during the study and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.
This study tests a new imaging agent that lights up certain proteins on solid tumors during a PET scan. It may help doctors better see tumors and guide treatment decisions.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.